Twist Bioscience CorpTWST
▲ PositiveDemandrelevance
New business from tech firms building genomic databases for AI models drives revenue growth.
Impact on stocks 1
Synthetic Biology (non-pharma)▲ · 1 stocks
Twist Bioscience CorpTheme Impact 2
Off-coverage companies
Related news
▲
Biological Computing Market to Reach $2.9 Billion by 2026
The global biological computing market is projected to grow from $2.21 billion in 2025 to $2.90 billion in 2026, a compound annual growth rate of 31.2%, according to a new report from ResearchAndMarkets.com. The market is forecast to reach $8.64 billion by 2030, expanding at a CAGR of 31.4% from 2026. Growth is driven by advances in DNA sequencing, synthetic biology, and bioinformatics, as well as demand for energy-efficient computing and personalized medicine. Key trends include DNA-based computing, synthetic biology-driven systems, and hybrid biological-digital platforms. Notable developments include FinalSpark's Neuroplatform for cloud-based biocomputing with human brain organoids and a partnership between VERSES Technologies and Cortical Labs to integrate AI with living neurons. North America led the market in 2025, while Asia-Pacific is expected to grow fastest. The report profiles major players such as Thermo Fisher Scientific, Illumina, and Ginkgo Bioworks.
▲2
Chuanning Biology first-half net profit 278 million yuan, synthetic biology revenue up 221%
Chuanning Biology disclosed its 2026 semi-annual report. In the first half of the year, it achieved total operating revenue of 2.098 billion yuan and net profit attributable to shareholders of the listed company of 278 million yuan. Second-quarter net profit was 167 million yuan, roughly flat compared with the same period last year and steadily higher than the first quarter. The company's synthetic biology production base in Gongliu County, Xinjiang, achieved operating revenue of 71.7599 million yuan in the first half, up 221.38% year on year. High-value-added products such as bisabolol, ergothioneine and squalane have already reached large-scale production. Domestic approval of ergothioneine as a new food ingredient has entered a critical stage and is expected to be formally approved in the second half of 2026.
5
Cathay Biotech first-half net profit 372 million yuan, up 20.75% year on year
Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.